The flavoenzyme N-ribosyldihydronicotinamide (NRH):quinone oxidoreductase 2 (NQO2) catalyzes two-electron reductions of quinones. NQO2 contributes to the metabolism of biogenic and xenobiotic quinones, including a wide range of antitumor drugs, with both toxifying and detoxifying functions. Moreover, NQO2 activity can be inhibited by several compounds, including drugs and phytochemicals such as flavonoids. NQO2 may play important roles that go beyond quinone metabolism and include the regulation of oxidative stress, inflammation, and autophagy, with implications in carcinogenesis and neurodegeneration. is a highly polymorphic gene with several allelic variants, including insertions (I), deletions (D) and single-nucleotide (SNP) polymorphisms located mainly in the promoter, but also in other regulatory regions and exons. This is the first systematic review of the literature reporting on NQO2 gene variants as risk factors in degenerative diseases or drug adverse effects. In particular, hypomorphic 29 bp I alleles have been linked to breast and other solid cancer susceptibility as well as to interindividual variability in response to chemotherapy. On the other hand, hypermorphic polymorphisms were associated with Parkinson's and Alzheimer's disease. The I and D promoter variants and other NQO2 polymorphisms may impact cognitive decline, alcoholism and toxicity of several nervous system drugs. Future studies are required to fill several gaps in NQO2 research.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10815803 | PMC |
| http://dx.doi.org/10.3390/genes15010087 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
FRK exerts oncogenic effects by targeting NQO2 via exosomal miR-9-3p to regulate mitochondrial function.
FASEB J
December 2024
Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Article Synopsis
- The study investigates how Fyn-related kinase (FRK) influences tumor growth and metabolism in non-small cell lung cancer (NSCLC) through exosomes.
- Exosomes from FRK-knockout cells were shown to negatively impact NSCLC cell activities like proliferation and metabolism, highlighting the role of exosomal miR-9-3p.
- The research suggests that FRK promotes NSCLC progression by regulating mitochondrial function via miR-9-3p targeting the protein NQO2.
Discovery of Potent Benzothiazole Inhibitors of Oxidoreductase NQO2, a Target for Inflammation and Cancer.
Int J Mol Sci
November 2024
Division of Pharmacy & Optometry, School of Health Sciences, University of Manchester, Manchester M13 9PT, UK.
Inhibitors of NQO2 (NRH: quinone oxidoreductase) have potential application in several areas of medicine and pharmacology, including cancer, neurodegeneration (PD and AD), stroke, and diabetes. Here, resveratrol, a known inhibitor of NQO2, was used as the lead by replacing the double bond in resveratrol with a benzothiazole scaffold. Fifty-five benzothiazoles were designed as NQO2 inhibitors and synthesized, comprising five benzothiazole series with 3,5-dimethoxy, 2,4-dimethoxy, 2,5-dimethoxy, 3,4-dimethoxy, and 3,4,5-trimethoxy substituents, the key synthetic step being a Jacobson cyclisation with the appropriate thiobenzamide.
View Article and Find Full Text PDFEvolutionary analysis of Quinone Reductases 1 and 2 suggests that NQO2 evolved to function as a pseudoenzyme.
Protein Sci
December 2024
Department of Biochemistry, University of Western Ontario, London, Ontario, Canada.
Quinone reductases 1 and 2 (NQO1 and NQO2) are paralogous FAD-linked enzymes found in all amniotes. NQO1 and NQO2 have similar structures, and both catalyze the reduction of quinones and other electrophiles; however, the two enzymes differ in their cosubstrate preference. While NQO1 can use both redox couples NADH and NADPH, NQO2 is almost inactive with these cosubstrates and instead must use dihydronicotinamide riboside (NRH) and small synthetic cosubstrates such as N-benzyl-dihydronicotinamide (BNAH) for efficient catalysis.
View Article and Find Full Text PDFIn vitro modelling of Parkinson's disease using 6-OHDA is associated with increased NQO2 activity.
Toxicol In Vitro
December 2024
Laboratory of Pharmacogenetics, Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies, Baltiyskaya Street 8, 125315 Moscow, Russia.
The pathogenesis of Parkinson's disease (PD) involves abnormalities in the metabolism of catecholamines. The enzyme quinone reductase 2 (NQO2) reduces quinone derivatives of catecholamines, which promotes the formation of reactive oxygen species (ROS), suggesting a role for NQO2 in the development of cellular damage typical of PD. In the present study, we investigated the relationship between 6-hydroxydophamine (6-OHDA) induced cellular damage and NQO2 activity and its levels in SH-SY5Y cell culture to establish an experimental model to evaluate the pharmacological properties of NQO2 inhibitors.
View Article and Find Full Text PDFMelatonin Receptor Expression in Primary Uveal Melanoma.
Int J Mol Sci
August 2024
Department of Clinical Neuroscience, Division of Eye and Vision, Karolinska Institutet, 171 77 Stockholm, Sweden.
Article Synopsis
- - The study investigates melatonin receptor expression in primary Uveal melanoma (UM) and its potential link to cancer mortality and prognosis.
- - Analysis of 47 UM tissue samples revealed low levels of melatonin receptors (MTNR1A and MTNR1B), with MTNR1A expression being higher in patients who died from UM.
- - Although melatonin receptors were present and some associations with specific mutations were noted, the research found no significant differences in survival rates based on receptor expression levels.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!